FundComb

Investment & M&A transaction comps

Consumer Health Investment & M&A Transaction Comps

Explore investment and M&A transactions tagged consumer health. Compare companies, buyers, dates and available valuation multiples, with reported, estimated or rumored figures clearly labelled in each comp.

Coverage includes published FundComb transactions carrying this tag. Each comp preserves its own source notes and valuation basis.

Explore 46 transactions ↓ Browse all comp sectors →
Reviewed transactions
46
With value data
29
With revenue multiples
24
Transaction years
2006–2026

Sortable transaction comps

Consumer Health transaction table

Filter transactions

Narrow the table without crowding the main view.

Clear all filters

Rows with reported value

13 / 25

Acquisition EV, USD

USD 76B

Investment EV, USD

-

Median EV / revenue

4.0x

Columns

Show columns

Select up to 12 rows across filters and pages, then share or export the set.

25 shown of 46 matching transactions. Click any transaction row for more detail.

Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately, and a financing without a reported valuation shows its amount raised, not an EV.

Select for comparison
Vitabiotics
Control
 2026-07-24 Bain Capital 1,038 - -
SupplementsConsumer Health
Lyons Magnus
Control
 2026-07-20 Truelink Capital Undisclosed - -
Food IngredientsBeveragesConsumer Health
4E Therapeutics
Control
 2026-06-16 Eli Lilly and Company Undisclosed - -
Consumer HealthBiotechPharma
2026-05-20 Medtronic Undisclosed - -
Consumer HealthMedtech
2026-02-12 Hindustan Unilever Limited (HUL) 186 3.5x -
BeautySports NutritionConsumer Health
Kenvue
Control (100%)
 2025-11-03 Kimberly-Clark 48,700 3.2x 14.3x
Personal CareConsumer Health
2025-06-27 Haleon plc Undisclosed - -
Consumer HealthPharma
Opella
Control (50%)
 2024-10-21 Clayton, Dubilier & Rice 17,365 3.1x 14.0x
SupplementsConsumer Health
2024-09-27 Haleon Undisclosed - -
Consumer HealthPharma
Bonafide Health
Control
 2023-11-30 Pharmavite 425 - -
SupplementsConsumer Health
2023-10-01 Cooper Consumer Health 2,066 - -
Consumer HealthPharma Services
Lamisil
Control
 2023-08-01 Karo Healthcare 300 4.1x -
Consumer Health
2023-04-28 Haleon plc Undisclosed - -
Consumer HealthManufacturing
Adare Biome
Control (100%)
 2023-04-19 dsm-firmenich AG 301 - 18.0x
SupplementsConsumer Health
Hilma
Control
 2022-11-17 Biocodex Undisclosed - -
SupplementsConsumer Health
2022-06-29 Nestle Undisclosed - -
FoodSupplementsConsumer Health
2021-10-11 Pacira BioSciences Undisclosed - 11.0x
Consumer HealthPharmaLife Sciences
2021-09-08 Perrigo 2,100 4.5x -
Skin CareConsumer Health
Uqora
Control
 2021-07-08 Pharmavite Undisclosed - -
SupplementsConsumer Health
2021-05-27 Prestige Consumer Healthcare 230 3.8x 11.5x
Consumer Health
Onnit Labs, Inc.
Control (100%)
 2021-04-26 Unilever Undisclosed - -
SupplementsConsumer Health
2021-03-12 CVC Capital Partners and Avista 2,611 4.4x 14.2x
Consumer Health
Welly
Control
 2021-02 Unilever Undisclosed - -
Consumer Health
Biofreeze
Control
 2021-02-01 Reckitt Benckiser Group plc 1,050 4.0x 29.0x
Consumer Health
Biogix, Inc.
Control
 2020-12-29 Alliance Pharma plc 110 5.0x 15.7x
SupplementsConsumer Health

Explore related tags

Continue to the full transaction history for each tag.

Consumer 34Supplements 19Vitamins 12CPG 7Pain Relief 5Pharma 5Cough & Cold 4Healthcare 4Women's Health 4Probiotics 3

Explore buyers & investors

Church & Dwight 3GlaxoSmithKline (GSK-Pfizer consumer joint venture) 3Haleon plc 3Reckitt Benckiser Group plc 3Unilever 3Nestle 2Pharmavite 2Alliance Pharma plc 1

Source coverage varies by transaction. Announced deals, minority investments and capital raises retain their own labels; an investment amount is separate from enterprise value. Read the methodology.

Values may be estimated, rumored, incomplete or derived from public information. Transaction comps are informational and should not be relied on as financial, investment or valuation advice.